Back

Renal function and hyperkalemia with first-line eplerenone in obese patients with hypertension: randomized safety data from the HEBRO trial

30 August 2026 (08:15 - 09:00)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy in hypertension Pharmacotherapy ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Panayiotis Iliakis

Hippokration General Hospital, Athens (Greece)

5 More presentations in this session

Presentation thumbnail
Baseline characteristics and antihypertensive patterns in Finnish patients with hypertension and kidney disease
Professor T. Niiranen (Turku, FI)
Abstract Slides Video
Presentation thumbnail
Artificial intelligence-assisted personalised dose titration for hypertension: safety and feasibility results of the CURATE.AI pilot randomised controlled trial
Doctor X. Tadeo (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Predicting individual blood pressure response to additional antihypertensive treatment: a prototype decision support tool for healthcare professionals in the community
Associate Professor A. Gupta (London, GB)
Abstract Slides Video
Presentation thumbnail
Digital AI lifestyle support improves blood pressure control on top of standard dual antihypertensive therapy
Mr B. Rozibaev (Tashkent, UZ)
Abstract Slides Video
Presentation thumbnail
Modifiable risk factors and 5-year and lifetime risks of cardiovascular disease among 0.5 million hypertensive patients in primary care
Doctor J. Wang (Beijing, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacotherapy in hypertension

The Event

Event poster

ESC Congress 2026

30 August 2026 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Eplerenone vs irbesartan as first line therapy in obese hypertensive patients: results of the HEBRO randomized controlled trial
28 August 2026
thumbnail
Congress Presentation
Real-world effectiveness and safety of finerenone in patients with chronic kidney disease and type 2 diabetes in the United States: A FOUNTAIN platform analysis
29 August 2026
thumbnail
Congress Presentation
Impact of renin-angiotensin system inhibitors in patients with heart failure with reduced ejection fraction and advanced chronic kidney disease
29 August 2026
thumbnail
Congress Presentation
Diuretic response and worsening renal function in obese patients with acute heart failure: a ROSE-AHF substudy
12 May 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources